4 years ago

SpyBiotech Raises $32.5 Million in Series A to Advance Vaccine Platform

  • SpyBiotech, a UK-based biotechnology company developing a novel vaccine platform technology, has secured $32.5 million in Series A funding

  • The round was led by Braavos Investment Advisers and joined by Oxford Investment Consultants

  • Existing investors Oxford Sciences Innovation, GV, and the UK Government's Future Fund also participated

  • The company plans to use the funds to advance clinical development of its vaccine platform and initiate a Phase I clinical trial for its lead candidate targeting human cytomegalovirus (HCMV) in early 2022.

      • ProblemHealthcare

      "Developing vaccines to target infectious diseases, cancer, and chronic diseases is a complex and time-consuming process, with many challenges in creating effective and safe vaccines. Current vaccine technologies often face limitations in terms of efficacy, stability, and manufacturability."

      Solution

      "SpyBiotech has developed a novel vaccine platform technology based on a protein “superglue” technology. This technology allows the display of target antigens on the surface of virus-like particles (VLPs), creating a highly immunogenic vaccine that can elicit a strong immune response. The company believes its platform can deliver vaccines with improved efficacy, stability, and manufacturability."

      Covered on